Compare McKesson Corporation (MCK) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Philip Morris International Inc. — how do they compare? McKesson Corporation trades at $829.95 (market cap $97.35B), while Philip Morris International Inc. trades at $192.33 (market cap $300.37B). The key difference: Philip Morris International Inc. is far larger — about 3.1× McKesson Corporation's market cap, and Philip Morris International Inc. pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| MCK | PM | |
|---|---|---|
Market Cap | $97.35B | $300.37B |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $192.98 |
52-Week Low | $659.01 | $144.33 |
Enterprise Value | $101.98B | $346.86B |
Dividend Yield | 0.39% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with a bullish technical signal and strong analyst consensus. Recent financials show robust revenue growth to $40.65B in 2025 and net income of $11.35B, though a Q4 2025 earnings miss and a recent $500M impairment charge highlight near-term pressures. The stock's P/E of 27.17 and P/S of 7.25 reflect premium valuation, supported by a 68% buy rating from analysts and a $194.00 consensus price target.
Outlook remains positive with steady cash flow and dividend payments, but risks include regulatory challenges from rising illicit cigarette trade in Europe and cost pressures. The stock offers stability through high margins and brand strength, yet investors should weigh valuation against earnings volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
